CorMedix (CRMD) Long-Term Deferred Tax (2015 - 2025)

CorMedix (CRMD) posted Long-Term Deferred Tax of $16.3 million for Q4 2025, down 69.0% sequentially from $52.5 million in Q3 2025.

CorMedix (CRMD) Long-Term Deferred Tax (2015 - 2025) Analysis & Trends

CorMedix has reported Long-Term Deferred Tax for 7 years, with the latest figure at $16.3 million in Q4 2025.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $16.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.3 million (changed N/A YoY) and the FY2025 annual result came in at $16.3 million, changed N/A from the prior year.
Long-Term Deferred Tax declined to $16.3 million in Q4 2025 per CRMD's latest filing, from $52.5 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $53.0 million in Q4 2021 and troughed at $16.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	CorMedix	645.20 Mn	388.51 Mn	77.13 Mn

Download Data